Search Results - "Lu, Cai‐Sheng"

Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome by Lu, Cai‐Sheng, Horizon, Arash A., Hwang, Kwan‐Ki, FitzGerald, John, Lin, Wei‐Shiang, Hahn, Bevra H., Wallace, Daniel J., Metzger, Allan L., Weisman, Michael H., Chen, Pojen P.

“…Objective To test the hypotheses that some plasmin‐reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of…”
Get full text

Acoustic emission assessment of interface cracking in thermal barrier coatings by Yang, Li, Zhong, Zhi-Chun, Zhou, Yi-Chun, Zhu, Wang, Zhang, Zhi-Biao, Cai, Can-Ying, Lu, Chun-Sheng

“…In this paper,acoustic emission（AE） and digital image correlation methods were applied to monitor interface cracking in thermal barrier coatings under…”
Get full text

Reliability assessment on interfacial failure of thermal barrier coatings by Guo, Jin-Wei, Yang, Li, Zhou, Yi-Chun, He, Li-Min, Zhu, Wang, Cai, Can-Ying, Lu, Chun-Sheng

“…Thermal barrier coatings（TBCs） usually exhibit an uncertain lifetime owing to their scattering mechanical properties and severe service conditions. To consider…”
Get full text

Screening of potential pseudo att sites of Streptomyces phage φC31 integrase in the human genome by Hu, Zhi-peng, Chen, Lu-sheng, Jia, Cai-yan, Zhu, Huan-zhang, Wang, Wei, Zhong, Jiang

“…Aim： φC31 integrase mediates site-specific recombination between two short sequences, attP and attB, in phage and bacterial genomes, which is a promising tool…”
Get full text

Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy： A Randomized Controlled Trial by Wu, Jie, Duan, Shu-Wei, Sun, Xue-Feng, Li, Wen-Ge, Wang, Ya-Ping, Liu, Wen-Hu, Zhang, Jian-Rong, Lun, Li-De, Li, Xue-Mei, Zhou, Chun-Hua, Li, Ji-Jun, Liu, Shu-Wen, Xie, Yuan-Sheng, Cai, Guang-Yan, Ma, Lu, Huang, Wen, Wu, Hua, Jia, Qiang, Chen, Xiang-Mei

“…Background： The efficacy and safety of telmisartan combined with clopidogrel, leflunomide, or both drugs for immunoglobulin A nephropathy （IgAN） are unclear…”
Get full text

Extremely low warfarin dose in patients with genotypes of CYP2C9＊3/＊3 and VKORCl-1639A/A by GAO Lei HE Lei LUO Jin XU Bin YANG Jie ZHANG Yu-xiao YANG Ting LI Ke TIAN Jin-wen WANG Hong-juan ZHAO Yu-sheng LU Cai-yi ZHANG Wen-zi YIN Tong

“…Background Patients with the genotypes of both CYP2C9＊3/＊3 and VKORC1-1639 A/A are expected to require the lowest dose of warfarin, and to have a greatly…”
Get full text

Identification of polyclonal and monoclonal antibodies against tissue-type plasminogen activator in the antiphospholipid syndrome by Lu, Cai-Sheng, Horizon, Arash A., Hwang, Kwan-Ki, FitzGerald, John, Lin, Wei-Shiang, Hahn, Bevra H., Wallace, Daniel J., Metzger, Allan L., Weisman, Michael H., Chen, Pojen P.

Get full text